The global market for CAR T-cell therapy in treating Non-Hodgkin's lymphoma is witnessing rapid growth. This phenomenon is fueled by several factors, including growing prevalence of Non-Hodgkin's lymphoma, developments in CAR T-cell therapy technology, and growing adoption by healthcare providers. The market is categorized based on factors such as